155 related articles for article (PubMed ID: 32391579)
1. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Lewis EC; Kraveka JM; Ferguson W; Eslin D; Brown VI; Bergendahl G; Roberts W; Wada RK; Oesterheld J; Mitchell D; Foley J; Zage P; Rawwas J; Rich M; Lorenzi E; Broglio K; Berry D; Saulnier Sholler GL
Int J Cancer; 2020 Dec; 147(11):3152-3159. PubMed ID: 32391579
[TBL] [Abstract][Full Text] [Related]
2. Maintenance DFMO Increases Survival in High Risk Neuroblastoma.
Sholler GLS; Ferguson W; Bergendahl G; Bond JP; Neville K; Eslin D; Brown V; Roberts W; Wada RK; Oesterheld J; Mitchell D; Foley J; Parikh NS; Eshun F; Zage P; Rawwas J; Sencer S; Pankiewicz D; Quinn M; Rich M; Junewick J; Kraveka JM
Sci Rep; 2018 Sep; 8(1):14445. PubMed ID: 30262852
[TBL] [Abstract][Full Text] [Related]
3. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J; Ferguson W; Kraveka JM; Bergendahl G; Clinch T; Lorenzi E; Berry D; Wada RK; Isakoff MS; Eslin DE; Brown VI; Roberts W; Zage P; Harrod VL; Mitchell DS; Hanson D; Saulnier Sholler GL
J Clin Oncol; 2024 Jan; 42(1):90-102. PubMed ID: 37883734
[TBL] [Abstract][Full Text] [Related]
4. A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Kraveka JM; Lewis EC; Bergendahl G; Ferguson W; Oesterheld J; Kim E; Nagulapally AB; Dykema KJ; Brown VI; Roberts WD; Mitchell D; Eslin D; Hanson D; Isakoff MS; Wada RK; Harrod VL; Rawwas J; Hanna G; Hendricks WPD; Byron SA; Snuderl M; Serrano J; Trent JM; Saulnier Sholler GL
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1616. PubMed ID: 35355452
[TBL] [Abstract][Full Text] [Related]
5. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Saulnier Sholler GL; Gerner EW; Bergendahl G; MacArthur RB; VanderWerff A; Ashikaga T; Bond JP; Ferguson W; Roberts W; Wada RK; Eslin D; Kraveka JM; Kaplan J; Mitchell D; Parikh NS; Neville K; Sender L; Higgins T; Kawakita M; Hiramatsu K; Moriya SS; Bachmann AS
PLoS One; 2015; 10(5):e0127246. PubMed ID: 26018967
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma.
Herd F; Basta NO; McNally RJQ; Tweddle DA
Eur J Cancer; 2019 Apr; 111():50-58. PubMed ID: 30822684
[TBL] [Abstract][Full Text] [Related]
7. The optimal timing of surgical resection in high-risk neuroblastoma.
Rojas Y; Jaramillo S; Lyons K; Mahmood N; Wu MF; Liu H; Vasudevan SA; Guillerman RP; Louis CU; Russell HV; Nuchtern JG; Kim ES
J Pediatr Surg; 2016 Oct; 51(10):1665-9. PubMed ID: 27318861
[TBL] [Abstract][Full Text] [Related]
8. Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Prados MD; Wara WM; Sneed PK; McDermott M; Chang SM; Rabbitt J; Page M; Malec M; Davis RL; Gutin PH; Lamborn K; Wilson CB; Phillips TL; Larson DA
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):71-7. PubMed ID: 11163499
[TBL] [Abstract][Full Text] [Related]
9. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.
Samal K; Zhao P; Kendzicky A; Yco LP; McClung H; Gerner E; Burns M; Bachmann AS; Sholler G
Int J Cancer; 2013 Sep; 133(6):1323-33. PubMed ID: 23457004
[TBL] [Abstract][Full Text] [Related]
10. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
Park JR; Kreissman SG; London WB; Naranjo A; Cohn SL; Hogarty MD; Tenney SC; Haas-Kogan D; Shaw PJ; Kraveka JM; Roberts SS; Geiger JD; Doski JJ; Voss SD; Maris JM; Grupp SA; Diller L
JAMA; 2019 Aug; 322(8):746-755. PubMed ID: 31454045
[TBL] [Abstract][Full Text] [Related]
11. Localized resectable neuroblastoma: results of the second study of the Italian Cooperative Group for Neuroblastoma.
De Bernardi B; Conte M; Mancini A; Donfrancesco A; Alvisi P; Tomà P; Casale F; Cordero di Montezemolo L; Cornelli PE; Carli M
J Clin Oncol; 1995 Apr; 13(4):884-93. PubMed ID: 7707115
[TBL] [Abstract][Full Text] [Related]
12. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
13. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
15. Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma.
Spasov N; Spasova M
Case Rep Pediatr; 2021; 2021():6610955. PubMed ID: 34239748
[TBL] [Abstract][Full Text] [Related]
16. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
17. Difluoromethylornithine (DFMO) and Neuroblastoma: A Review.
Tangella AV; Gajre AS; Chirumamilla PC; Rathhan PV
Cureus; 2023 Apr; 15(4):e37680. PubMed ID: 37206500
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness.
Milord F; Pépin J; Loko L; Ethier L; Mpia B
Lancet; 1992 Sep; 340(8820):652-5. PubMed ID: 1355219
[TBL] [Abstract][Full Text] [Related]
19. Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.
London WB; Bagatell R; Weigel BJ; Fox E; Guo D; Van Ryn C; Naranjo A; Park JR
Cancer; 2017 Dec; 123(24):4914-4923. PubMed ID: 28885700
[TBL] [Abstract][Full Text] [Related]
20. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.
West DC; Shamberger RC; Macklis RM; Kozakewich HP; Wayne AS; Kreissman SG; Korf BR; Lavally B; Grier HE
J Clin Oncol; 1993 Jan; 11(1):84-90. PubMed ID: 8418247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
